Benznidazole

Discontinue at first sign of serious cutaneous reactions (eg, AGEP, TEN, erythema multiforme, eosinophilic drug reaction), skin reactions presenting additional signs of systemic involvement (eg, lymphadenopathy, fever, purpura), or if neurological symptoms occur. Hematological manifestations of bone marrow depression: treat under strict medical supervision. Monitor CBC, total and differential leukocyte counts before, during and after therapy. Hepatic or renal impairment. Potential for genotoxicity. Embryo-fetal toxicity. Pregnancy: exclude status prior to initiation. Advise females of reproductive potential to use effective contraception during and for 5 days after the last dose. Nursing mothers: not recommended.